Auris Medical (NASDAQ:EARS) released its quarterly earnings data on Thursday. The biotechnology company reported ($0.12) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.01), MarketWatch Earnings reports.
Shares of NASDAQ:EARS traded down $0.01 on Friday, hitting $0.40. The company had a trading volume of 7,027 shares, compared to its average volume of 1,787,490. Auris Medical has a 1-year low of $0.23 and a 1-year high of $3.08. The company has a market cap of $15.19 million, a P/E ratio of -0.07 and a beta of -0.56.
Several research firms have commented on EARS. Zacks Investment Research upgraded shares of Auris Medical from a “hold” rating to a “buy” rating and set a $0.50 price objective on the stock in a report on Tuesday, January 1st. ValuEngine upgraded shares of Auris Medical from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. Finally, Roth Capital began coverage on shares of Auris Medical in a report on Thursday, December 20th. They issued a “buy” rating and a $5.00 price objective on the stock.
Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss.
Further Reading: Bear Market – How and Why They Occur
Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with MarketBeat.com's FREE daily email newsletter.